AKKARAJU SRINIVAS 4
4 · Scholar Rock Holding Corp · Filed Dec 16, 2025
Insider Transaction Report
Form 4
AKKARAJU SRINIVAS
Director
Transactions
- Purchase
Common Stock
2025-10-07$39.31/sh+12,796$503,011→ 513,235 total(indirect: By Samsara Opportunity Fund, L.P.) - Purchase
Common Stock
2025-10-07$40.18/sh+12,400$498,232→ 525,635 total(indirect: By Samsara Opportunity Fund, L.P.) - Purchase
Common Stock
2025-10-07$40.97/sh+4,403$180,391→ 530,038 total(indirect: By Samsara Opportunity Fund, L.P.) - Exercise of In-Money
Common Stock
2025-12-12$7.35/sh+1,064,804$7,826,309→ 6,367,614 total(indirect: By Samsara BioCapital, L.P.) - Exercise of In-Money
Warrants to Purchase Common Stock
2025-12-12−1,064,804→ 0 total(indirect: By Samsara BioCapital LP)Exercise: $7.35From: 2022-06-22Exp: 2025-12-31→ Common Stock (1,064,804 underlying)
Holdings
- 21,132
Common Stock
Footnotes (5)
- [F1]The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $38.85 to $39.849 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote.
- [F2]Securities are directly held by Samsara Opportunity Fund, L.P. ("Samsara Opportunity Fund"). Samsara Opportunity Fund GP, LLC ("Samsara Opportunity GP") is the general partner of Samsara Opportunity Fund and may be deemed to beneficially own the securities held by Samsara Opportunity Fund. The Reporting Person has voting and investment power over the securities held by Samsara Opportunity Fund and, accordingly, may be deemed to beneficially own the securities held by Samsara Opportunity Fund. The Reporting Person disclaims beneficial ownership in these securities except to the extent of his pecuniary interest therein.
- [F3]The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $39.8512 to $40.85 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote.
- [F4]The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $40.87 to $41.00 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote.
- [F5]Securities are directly held by Samsara BioCapital LP ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the securities held by Samsara LP. The Reporting Person has voting and investment power over the securities held by Samsara LP and, accordingly, may be deemed to beneficially own the securities held by Samsara LP. The Reporting Person disclaims beneficial ownership in these securities except to the extent of his pecuniary interest therein.